<div class="tables frame-topbot colsep-0 rowsep-0" id="tbl5">
<div class="captions"><span id="cap0050"><p id="tspara0070"><span class="label">Table 5</span>. The Most Severe eGFR Grade During Follow-Up According to <a href="https://www.sciencedirect.com/topics/nursing-and-health-professions/randomization" title="Learn more about Randomization from ScienceDirect's AI-generated Topic Pages">Random Allocation</a><span> to Placebo or <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/canakinumab" title="Learn more about Canakinumab from ScienceDirect's AI-generated Topic Pages">Canakinumab</a></span></p></span></div>
<div class="groups"><table>
<thead>
<tr class="rowsep-1 valign-top">
<th scope="col" rowspan="2">eGFR Grade</th>
<th scope="col" rowspan="2">Placebo</th>
<th scope="col" colspan="4">Canakinumab Dose</th>
</tr>
<tr class="rowsep-1 valign-top">
<th scope="col">50 mg</th>
<th scope="col">150 mg</th>
<th scope="col">300 mg</th>
<th scope="col">All Doses</th>
</tr>
</thead>
<tbody>
<tr class="valign-top">
<td>Stage 3: eGFR 30–60 ml/min/1.73 m<sup>2</sup>
</td>
<td class="align-center">1,247 (37.5)</td>
<td class="align-center">883 (41.0)</td>
<td class="align-center">920 (40.5)</td>
<td class="align-center">899 (40.0)</td>
<td class="align-center">2,702 (40.5)</td>
</tr>
<tr class="valign-top">
<td>Stage 4: eGFR 15–29 ml/min/1.73 m<sup>2</sup>
</td>
<td class="align-center">145 (4.4)</td>
<td class="align-center">75 (3.5)</td>
<td class="align-center">86 (3.8)</td>
<td class="align-center">206 (4.7)</td>
<td class="align-center">266 (4.0)</td>
</tr>
<tr class="valign-top">
<td>Stage 5: eGFR &lt;15 ml/min/1.73 m<sup>2</sup>
</td>
<td class="align-center">14 (0.4)</td>
<td class="align-center">10 (0.5)</td>
<td class="align-center">14 (0.6)</td>
<td class="align-center">7 (0.3)</td>
<td class="align-center">31 (0.5)</td>
</tr>
<tr class="valign-top">
<td>Post-randomization dialysis</td>
<td class="align-center">13 (0.4)</td>
<td class="align-center">6 (0.3)</td>
<td class="align-center">4 (0.2)</td>
<td class="align-center">6 (0.3)</td>
<td class="align-center">16 (0.2)</td>
</tr>
</tbody>
</table></div>
<p class="legend"></p>
<p id="tspara0075">Values
 are n (%) and are shown for the most severe stage of eGFR observed for 
each individual trial participant in the full CANTOS safety analysis set
 during the study period and for participants undergoing <a href="https://www.sciencedirect.com/topics/nursing-and-health-professions/dialysis" title="Learn more about Dialysis from ScienceDirect's AI-generated Topic Pages">dialysis</a> after randomization.</p>
<p id="tspara0080">CANTOS = Canakinumab Anti-Inflammatory <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/thrombosis" title="Learn more about Thrombosis from ScienceDirect's AI-generated Topic Pages">Thrombosis</a><span> Outcomes Study; eGFR = estimated <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/glomerular-filtration-rate" title="Learn more about Glomerular Filtration Rate from ScienceDirect's AI-generated Topic Pages">glomerular filtration rate</a>.</span></p>
<p></p>
</div>